Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-11 inhibit the growth of androgen-independent PC- 3 prostate cancer in nude mice

Andreas Jungwirth, Georg Galvan, Jacek Pinski, Gabor Halmos, Karoly Szepeshazi, Ren Zhi Cai, Kate Groot, Andrew V Schally

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

BACKGROUND. Hormones like bombesin (BN)/gastrin-releasing peptide (GRP) and luteinizing hormone-releasing hormone (LH-RH) and growth factors such as epidermal growth factor (EGF) might be involved in the relapse of prostate cancer under androgen ablation therapy. Interference with receptors for BN/GRP, LH-RH, or EGF might provide a therapeutic approach to inhibit tumor growth of androgen-independent prostate cancer. METHODS. LH-RH antagonist Cetrorelix (SB-75) and the BN/GRP antagonist RC-3940-II were tested for their effects on the growth of the androgen-independent PC-3 human prostate cancer cell line xenografted into nude mice. Tumor growth, serum hormone levels, and receptor concentrations for BN/GRP and EGF were measured. RESULTS. When the treatment was started, tumor volume in all groups was 70-80 mm3. After 4 weeks, tumor volume in the control animals injected with saline was 871 ± 233 mm3 and that of animals treated with Cetrorelix only 197 ± 61 mm3. The BN/GRP antagonist RC-3940-II also significantly reduced PC-3 tumor volume in nude mice to 122 ± 20 mm3. The combination of Cetrorelix and RC-3940-II produced no additional inhibition. High-affinity receptors for EGF were detected in the tumor membranes and their number was significantly decreased after administration of Cetrorelix or RC-3940-II. CONCLUSIONS. These findings demonstrate that LH-RH antagonists and BN/GRP antagonists inhibit the growth of the androgen-independent prostate cancer cell line PC-3 in vivo. Both analogs may exert a direct inhibitory effect on tumor growth through a down- regulation of EGF receptors.

Original languageEnglish
Pages (from-to)164-172
Number of pages9
JournalProstate
Volume32
Issue number3
DOIs
StatePublished - Aug 1 1997
Externally publishedYes

Fingerprint

Gastrin-Releasing Peptide
Hormone Antagonists
Bombesin
Nude Mice
Gonadotropin-Releasing Hormone
Androgens
Prostatic Neoplasms
Tumor Burden
Epidermal Growth Factor
Bombesin Receptors
Growth
Peptide Hormones
Neoplasms
Cholecystokinin B Receptor
Cell Line
Growth Hormone
Intercellular Signaling Peptides and Proteins
Down-Regulation
cetrorelix
Hormones

Keywords

  • Bombesin antagonist
  • Cetrorelix
  • LH-RH antagonist
  • Nude mouse
  • PC-3 tumor
  • Peptide antagonists
  • Prostatic cancer
  • Xenografts

ASJC Scopus subject areas

  • Urology

Cite this

Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-11 inhibit the growth of androgen-independent PC- 3 prostate cancer in nude mice. / Jungwirth, Andreas; Galvan, Georg; Pinski, Jacek; Halmos, Gabor; Szepeshazi, Karoly; Cai, Ren Zhi; Groot, Kate; Schally, Andrew V.

In: Prostate, Vol. 32, No. 3, 01.08.1997, p. 164-172.

Research output: Contribution to journalArticle

Jungwirth, Andreas ; Galvan, Georg ; Pinski, Jacek ; Halmos, Gabor ; Szepeshazi, Karoly ; Cai, Ren Zhi ; Groot, Kate ; Schally, Andrew V. / Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-11 inhibit the growth of androgen-independent PC- 3 prostate cancer in nude mice. In: Prostate. 1997 ; Vol. 32, No. 3. pp. 164-172.
@article{483720cf63974c7ba2ac06d093b8bed6,
title = "Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-11 inhibit the growth of androgen-independent PC- 3 prostate cancer in nude mice",
abstract = "BACKGROUND. Hormones like bombesin (BN)/gastrin-releasing peptide (GRP) and luteinizing hormone-releasing hormone (LH-RH) and growth factors such as epidermal growth factor (EGF) might be involved in the relapse of prostate cancer under androgen ablation therapy. Interference with receptors for BN/GRP, LH-RH, or EGF might provide a therapeutic approach to inhibit tumor growth of androgen-independent prostate cancer. METHODS. LH-RH antagonist Cetrorelix (SB-75) and the BN/GRP antagonist RC-3940-II were tested for their effects on the growth of the androgen-independent PC-3 human prostate cancer cell line xenografted into nude mice. Tumor growth, serum hormone levels, and receptor concentrations for BN/GRP and EGF were measured. RESULTS. When the treatment was started, tumor volume in all groups was 70-80 mm3. After 4 weeks, tumor volume in the control animals injected with saline was 871 ± 233 mm3 and that of animals treated with Cetrorelix only 197 ± 61 mm3. The BN/GRP antagonist RC-3940-II also significantly reduced PC-3 tumor volume in nude mice to 122 ± 20 mm3. The combination of Cetrorelix and RC-3940-II produced no additional inhibition. High-affinity receptors for EGF were detected in the tumor membranes and their number was significantly decreased after administration of Cetrorelix or RC-3940-II. CONCLUSIONS. These findings demonstrate that LH-RH antagonists and BN/GRP antagonists inhibit the growth of the androgen-independent prostate cancer cell line PC-3 in vivo. Both analogs may exert a direct inhibitory effect on tumor growth through a down- regulation of EGF receptors.",
keywords = "Bombesin antagonist, Cetrorelix, LH-RH antagonist, Nude mouse, PC-3 tumor, Peptide antagonists, Prostatic cancer, Xenografts",
author = "Andreas Jungwirth and Georg Galvan and Jacek Pinski and Gabor Halmos and Karoly Szepeshazi and Cai, {Ren Zhi} and Kate Groot and Schally, {Andrew V}",
year = "1997",
month = "8",
day = "1",
doi = "10.1002/(SICI)1097-0045(19970801)32:3<164::AID-PROS2>3.0.CO;2-L",
language = "English",
volume = "32",
pages = "164--172",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-11 inhibit the growth of androgen-independent PC- 3 prostate cancer in nude mice

AU - Jungwirth, Andreas

AU - Galvan, Georg

AU - Pinski, Jacek

AU - Halmos, Gabor

AU - Szepeshazi, Karoly

AU - Cai, Ren Zhi

AU - Groot, Kate

AU - Schally, Andrew V

PY - 1997/8/1

Y1 - 1997/8/1

N2 - BACKGROUND. Hormones like bombesin (BN)/gastrin-releasing peptide (GRP) and luteinizing hormone-releasing hormone (LH-RH) and growth factors such as epidermal growth factor (EGF) might be involved in the relapse of prostate cancer under androgen ablation therapy. Interference with receptors for BN/GRP, LH-RH, or EGF might provide a therapeutic approach to inhibit tumor growth of androgen-independent prostate cancer. METHODS. LH-RH antagonist Cetrorelix (SB-75) and the BN/GRP antagonist RC-3940-II were tested for their effects on the growth of the androgen-independent PC-3 human prostate cancer cell line xenografted into nude mice. Tumor growth, serum hormone levels, and receptor concentrations for BN/GRP and EGF were measured. RESULTS. When the treatment was started, tumor volume in all groups was 70-80 mm3. After 4 weeks, tumor volume in the control animals injected with saline was 871 ± 233 mm3 and that of animals treated with Cetrorelix only 197 ± 61 mm3. The BN/GRP antagonist RC-3940-II also significantly reduced PC-3 tumor volume in nude mice to 122 ± 20 mm3. The combination of Cetrorelix and RC-3940-II produced no additional inhibition. High-affinity receptors for EGF were detected in the tumor membranes and their number was significantly decreased after administration of Cetrorelix or RC-3940-II. CONCLUSIONS. These findings demonstrate that LH-RH antagonists and BN/GRP antagonists inhibit the growth of the androgen-independent prostate cancer cell line PC-3 in vivo. Both analogs may exert a direct inhibitory effect on tumor growth through a down- regulation of EGF receptors.

AB - BACKGROUND. Hormones like bombesin (BN)/gastrin-releasing peptide (GRP) and luteinizing hormone-releasing hormone (LH-RH) and growth factors such as epidermal growth factor (EGF) might be involved in the relapse of prostate cancer under androgen ablation therapy. Interference with receptors for BN/GRP, LH-RH, or EGF might provide a therapeutic approach to inhibit tumor growth of androgen-independent prostate cancer. METHODS. LH-RH antagonist Cetrorelix (SB-75) and the BN/GRP antagonist RC-3940-II were tested for their effects on the growth of the androgen-independent PC-3 human prostate cancer cell line xenografted into nude mice. Tumor growth, serum hormone levels, and receptor concentrations for BN/GRP and EGF were measured. RESULTS. When the treatment was started, tumor volume in all groups was 70-80 mm3. After 4 weeks, tumor volume in the control animals injected with saline was 871 ± 233 mm3 and that of animals treated with Cetrorelix only 197 ± 61 mm3. The BN/GRP antagonist RC-3940-II also significantly reduced PC-3 tumor volume in nude mice to 122 ± 20 mm3. The combination of Cetrorelix and RC-3940-II produced no additional inhibition. High-affinity receptors for EGF were detected in the tumor membranes and their number was significantly decreased after administration of Cetrorelix or RC-3940-II. CONCLUSIONS. These findings demonstrate that LH-RH antagonists and BN/GRP antagonists inhibit the growth of the androgen-independent prostate cancer cell line PC-3 in vivo. Both analogs may exert a direct inhibitory effect on tumor growth through a down- regulation of EGF receptors.

KW - Bombesin antagonist

KW - Cetrorelix

KW - LH-RH antagonist

KW - Nude mouse

KW - PC-3 tumor

KW - Peptide antagonists

KW - Prostatic cancer

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=0030751523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030751523&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(19970801)32:3<164::AID-PROS2>3.0.CO;2-L

DO - 10.1002/(SICI)1097-0045(19970801)32:3<164::AID-PROS2>3.0.CO;2-L

M3 - Article

VL - 32

SP - 164

EP - 172

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 3

ER -